✦ LIBER ✦

The OPTimization of Interferon for MS Study: 375 μg interferon beta-1b in suboptimal responders

✍ Scribed by L. Durelli; P. Barbero; M. Bergui; E. Versino; M. A. Bassano; E. Verdun; B. Ferrero; C. Rivoiro; C. Ferrero; E. Picco; P. Ripellino; D. Viglietti; G. Giuliani; E. Montanari; M. Clerico; for the OPTIMS Study Group*

Book ID: 106094017
Publisher: Springer
Year: 2008
Tongue: English
Weight: 283 KB
Volume: 255
Category: Article
ISSN: 0340-5354
DOI: 10.1007/s00415-008-0879-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Subgroups of the BENEFIT study: Risk of

Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b

✍ C. Polman; L. Kappos; M. S. Freedman; G. Edan; H.-P. Hartung; D. H. Miller; X. M 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 321 KB

Interferon beta treatment of MS in the d

Interferon beta treatment of MS in the daily clinical setting: a 3-year post-marketing study

✍ E. Onesti; F. Bagnato; V. Tomassini; G. Volante; F. Denaro; M. Frontoni; E. Mill 📂 Article 📅 2003 🏛 Springer Milan 🌐 English ⚖ 93 KB

A case study on the effect of neutralizi

A case study on the effect of neutralizing antibodies to interferon beta 1b in multiple sclerosis patients followed for 3 years with monthly imaging

✍ A. W. Chiu; M. Ehrmantraut; N. D. Richert; V. N. Ikonomidou; S. Pellegrini; H. F 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB

Comparison of two PEG-interferon alpha-2

Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 μg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis

✍ B. Meyer-Wyss; P. Rich; Hp Egger; B. Helbling; B. Müllhaupt; C. Rammert; J.-J. G 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 220 KB